LDLR, Recombinant Protein

LDLR; FH; FHC; LDLCQ2; Low-Density Lipoprotein (LDL) Receptor

For Research Use Only. Not for use in diagnostic procedures.

HEK293 cells

>=90%

Lyophilized from 0.22 mum filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.
Appearance: Lyophilized

At -20 degree C
Shelf Life: 12 months

Small volumes of LDLR recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Background: Low-Density Lipoprotein (LDL) Receptor, also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

Proteins and Enzymes; Human cell expressed recombinant proteinsProteins and Enzymes; Proteins and Enzymes (A-Z)Proteins and Enzymes; Other Proteins & EnzymesDiabetes, Obesity & Metabolic Syndrome; Lipids Metabolism; Proteins/Enzymes; Other (NEW)

SDS-PAGE

This protein is fused with a C-terminal 6×his tag and has a calculated MW of 86 kDa. The predicted N-terminal is Ala22 or Asp193. Corresponding to the mature and immature form, DTT-reduced protein migrates as 95-110 kDa &125-140 kDa polypeptide in SDS-PAG

low density lipoprotein receptor

low-density lipoprotein receptor

Low-density lipoprotein receptor

LDL receptor  [Similar Products]

LDLR_HUMAN

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010]

LDLR: Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. In case of HIV-1 infection, functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells. Defects in LDLR are the cause of familial hypercholesterolemia (FH); a common autosomal semi- dominant disease that affects about 1 in 500 individuals. The receptor defect impairs the catabolism of LDL, and the resultant elevation in plasma LDL-cholesterol promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and coronary arteries (atherosclerosis). Belongs to the LDLR family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Receptor, misc.; Membrane protein, integral; Cell surface

Chromosomal Location of Human Ortholog: 19p13.2

Cellular Component: Golgi apparatus; cell surface; membrane; integral to plasma membrane; lysosome; late endosome; early endosome; plasma membrane; endosome membrane; coated pit; receptor complex; external side of plasma membrane

Molecular Function: very-low-density lipoprotein receptor activity; low-density lipoprotein receptor activity; protein binding; low-density lipoprotein binding; calcium ion binding; clathrin heavy chain binding; glycoprotein binding

Biological Process: receptor-mediated endocytosis; cholesterol metabolic process; phototransduction, visible light; lipoprotein catabolic process; cholesterol transport; viral reproduction; cholesterol absorption; endocytosis; lipoprotein metabolic process; cholesterol homeostasis; phospholipid transport; lipid metabolic process; retinoid metabolic process

Disease: Hypercholesterolemia, Familial

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.